Thursday, November 10, 2016

BRIEF-Theratechnologies gives results of late stage HIV study

* Theratechnologies inc says ibalizumab maintains

significant reduction of viral load in patients with multi-drug

resistant hiv-1 over 24 weeks

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)